查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1574973

抗心律不整药物市场，按药物类别、按给药途径、按适应症、按配销通路、按国家和地区划分 - 2024-2032 年行业分析、市场规模、市场份额和预测

Antiarrhythmic Drugs Market, By Drug Class, By Route of Administration, By Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 311 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年抗心律不整药物市场规模为1,04,732万美元，2024年至2032年复合年增长率为6.60%。

抗心律不整药物市场-市场动态

心血管疾病盛行率上升推动抗心律不整药物市场成长

心房颤动、心室性心律不整和心搏过速等心血管疾病 (CVD) 的盛行率不断增加，推动了抗心律不整药物的需求。在全球范围内，世界卫生组织 (WHO) 等组织报告称，CVD 仍然是死亡的主要原因，每年约有 1,790 万人因此丧生。抗心律不整药物在恢復正常心律和预防危及生命的併发症方面发挥着至关重要的作用。例如，胺碘酮和氟卡尼通常用于治疗心律不整。各国政府和医疗保健提供者正致力于心律不整的早期诊断和治疗，以降低与心血管疾病相关的死亡率，从而为抗心律不整药物市场创造新的机会。此外，药物配方的进步，例如更有针对性的治疗，正在支持该领域的成长。

抗心律不整药物市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032）每年将以 6.60% 左右的复合年增长率成长

根据药物类别细分，钠通道阻断剂预计将在 2023 年显示最大的市场份额

根据给药途径细分，2023年口服是领先类型

根据适应症细分，心房颤动是2023年的主导类型

按地区划分，北美是 2023 年的主要收入来源

抗心律不整药物市场-細項分析：

全球抗心律不整药物市场依据药物类别、给药途径、适应症、配销通路和地区进行细分。

依药物类别，市场分为四类：钠通道阻断剂、β-阻断剂、钾通道阻断剂、钙通道阻断剂。钠通道阻断剂由于广泛用于治疗心律不整而具有最高优先级，其次是钾通道阻断剂和β-阻断剂，因其功效而闻名。相比之下，钙通道阻断剂排名较低。

根据给药途径，市场分为三类：口服、注射和经皮。由于方便和患者偏好，口服给药具有最高优先级，其次是注射剂型以满足更直接的治疗需求。经皮给药的使用率较低，但在某些情况下越来越受到关注。

抗心律不整药物市场-地理洞察

抗心律不整药物市场呈现出显着的地理差异，由于心血管疾病的高盛行率和强大的医疗基础设施，北美在 2023 年将处于领先地位。美国心臟协会报告称，美国有近 270 至 610 万人患有心房颤动，这是抗心律不整药物需求的主要驱动力。欧洲紧随其后，并得到欧洲心臟病学会 (ESC) 旨在加强心律不整管理和研究的计划等倡议的支持。在亚太地区，快速的城市化和生活方式的改变增加了心血管疾病的风险，中国和印度等国家对抗心律不整治疗的需求不断增长。亚太地区也受益于旨在改善医疗保健可近性的政府计划，例如印度的 Ayushman Bharat 计划，该计划专注于提供负担得起的医疗服务。拉丁美洲、中东和非洲地区呈现温和成长，医疗基础设施投资不断增加，人们对心臟病治疗的认识不断提高，刺激了这些地区对抗心律不整药物的需求。

抗心律不整药物市场-竞争格局：

抗心律不整药物市场的竞争格局以活跃的活动为标誌，北美在创新和策略合作方面处于领先地位。例如，辉瑞（Pfizer）和安进（Amgen）等美国製药巨头一直处于开发先进抗心律不整治疗的前沿。 2022年，辉瑞宣布与百时美施贵宝建立战略合作关係，以扩大其心血管药物组合，该药物也针对心律不整。欧洲紧随其后，赛诺菲和诺华等公司积极参与研究合作，以提高药物疗效和病患治疗效果。最近，诺华在欧洲市场推出了一款旨在减少心房颤动復发的新药，解决了重大未满足的需求。亚太地区正迅速成为关键地区，武田製药等地区企业对研发的投资不断增加。 2023年，武田宣布与当地一家生技公司合併，以扩大其心血管药物组合，这标誌着该地区抗心律不整药物市场的竞争和创新加剧。

最新进展：

2024 年 5 月，Milestone Pharmaceuticals Inc. 与心律不整联盟合作，提高人们对室上性心搏过速 (SVT) 的认识。此次合作旨在改善对该疾病的教育和了解，突显 Milestone 对创新心血管治疗的承诺。

2023 年 12 月，专注于心房颤动创新疗法的生物技术公司 Acesion Pharma 宣布在《Nature Medicine》上发表其突破性 SK 离子通道抑制剂 AP30663 的 2 期概念验证试验结果。

目录

第一章：抗心律不整药物市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按药物类别分類的抗心律不整药物市场片段
    • 依给药途径分類的抗心律不整药物市场片段
    • 以适应症分類的抗心律不整药物市场片段
    • 按配销通路分類的抗心律不整药物市场片段
    • 按国家/地区分類的抗心律不整药物市场片段
    • 按地区分類的抗心律不整药物市场片段
  • 竞争洞察

第 3 章：抗心律不整药物主要市场趋势

  • 抗心律不整药物市场驱动因素
    • 市场驱动因素的影响分析
  • 抗心律不整药物市场限制
    • 市场限制影响分析
  • 抗心律不整药物市场机会
  • 抗心律不整药物市场未来趋势

第 4 章：抗心律不整药物产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：抗心律不整药物市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：抗心律不整药物市场格局

  • 2023 年抗心律不整药物市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：抗心律不整药物市场 - 按药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 钠通道阻断剂
    • β-受体阻断剂
    • 钾通道阻断剂
    • 钙通道阻断剂

第 8 章：抗心律不整药物市场 - 按给药途径

  • 概述
    • 按给药途径分類的细分市占率分析
    • 口服
    • 可注射
    • 透皮

第 9 章：抗心律不整药物市场 - 按适应症

  • 概述
    • 按指标分類的细分市场占有率分析
    • 心房震颤
    • 室性心搏过速
    • 心室上性心搏过速
    • 其他

第 10 章：抗心律不整药物市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 网路药局

第 11 章：抗心律不整药物市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美抗心律不整药物主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模和预测（按指标）
    • 北美市场规模和预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲抗心律不整药物主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模与预测（按指标）
    • 欧洲市场规模和预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区抗心律不整药物主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模与预测（依指标）
    • 亚太地区市场规模和预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲抗心律不整药物主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模与预测（按指标）
    • 拉丁美洲市场规模和预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲抗心律不整药物主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模及预测（依指标）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 12 章：主要供应商分析 - 抗心律不整药物产业

  • 竞争仪表板
  • 公司简介
    • Abbott Laboratories
    • Amgen Inc.
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Harlan Laboratories, Inc.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • Others

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV3966

REPORT HIGHLIGHT

Antiarrhythmic Drugs Market size was valued at USD 1,047.32 million in 2023, expanding at a CAGR of 6.60% from 2024 to 2032.

The Antiarrhythmic Drugs Market focuses on medications used to treat abnormal heart rhythms (arrhythmias), which are conditions where the heart beats irregularly, too fast, or too slow. These drugs are essential for preventing complications like stroke and heart failure. The increasing prevalence of cardiovascular diseases globally has been a significant growth factor, with atrial fibrillation affecting more than 33 million people worldwide. However, side effects associated with antiarrhythmic drugs and the availability of alternative treatments, such as catheter ablation, act as restraints. Opportunities lie in the development of new and safer antiarrhythmic drugs and the growing demand for minimally invasive treatments. Government health initiatives and rising geriatric populations further support market expansion, particularly in regions like North America and Europe.

Antiarrhythmic Drugs Market- Market Dynamics

Rising Prevalence of Cardiovascular Diseases Fuels Growth in the Antiarrhythmic Drugs Market

The increasing prevalence of cardiovascular diseases (CVDs), such as atrial fibrillation, ventricular arrhythmias, and tachycardia, is driving the demand for antiarrhythmic drugs. Globally, organizations like the World Health Organization (WHO) report that CVDs remain the leading cause of death, responsible for approximately 17.9 million lives annually. Antiarrhythmic drugs play a crucial role in restoring normal heart rhythm and preventing life-threatening complications. For example, Amiodarone and Flecainide are commonly prescribed to manage irregular heartbeats. Governments and healthcare providers are focusing on early diagnosis and treatment of arrhythmias to reduce CVD-related mortality, creating new opportunities in the antiarrhythmic drugs market. Additionally, advancements in drug formulations, such as more targeted therapies, are supporting growth in this sector.

Antiarrhythmic Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.60% over the forecast period (2024-2032)

Based on Drug Class segmentation, Sodium Channel Blockers was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on Indication segmentation, Atrial Fibrillation was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Antiarrhythmic Drugs Market- Segmentation Analysis:

The Global Antiarrhythmic Drugs Market is segmented on the basis of Drug Class, Route of Administration, Indication, Distribution Channel, and Region.

The market is divided into four categories based on Drug Class: Sodium Channel Blockers, Beta-Blockers, Potassium Channel Blockers, and Calcium Channel Blockers. Sodium Channel Blockers held the highest priority due to their widespread use in managing arrhythmias, followed by Potassium Channel Blockers and Beta-Blockers, known for their efficacy. Calcium Channel Blockers ranked lower in comparison.

The market is divided into three categories based on the Route of Administration: Oral, Injectable, and Transdermal. Oral administration held the highest priority due to convenience and patient preference, followed by Injectable forms for more immediate treatment needs. Transdermal administration ranked lower in usage but is gaining interest for certain conditions.

Antiarrhythmic Drugs Market- Geographical Insights

The antiarrhythmic drugs market shows significant geographical variation, with North America leading in 2023 due to the high prevalence of cardiovascular diseases and robust healthcare infrastructure. The American Heart Association reports that nearly 2.7 to 6.1 million people in the U.S. suffer from atrial fibrillation, a key driver for antiarrhythmic drug demand. Europe follows closely, supported by initiatives such as the European Society of Cardiology's (ESC) programs to enhance arrhythmia management and research. In Asia-Pacific, rapid urbanization and lifestyle changes have increased the risk of cardiovascular diseases, with countries like China and India witnessing growing demand for antiarrhythmic treatments. The Asia-Pacific region is also benefiting from government programs aimed at improving healthcare access, such as India's Ayushman Bharat scheme, which focuses on providing affordable medical care. Latin America and the Middle East & Africa show moderate growth, with increasing investments in healthcare infrastructure and rising awareness about heart disease treatments fueling demand for antiarrhythmic drugs in these regions.

Antiarrhythmic Drugs Market- Competitive Landscape:

The competitive landscape of the antiarrhythmic drugs market is marked by significant activity, with North America leading in terms of innovation and strategic collaborations. For instance, U.S.-based pharmaceutical giants such as Pfizer and Amgen have been at the forefront of developing advanced antiarrhythmic treatments. In 2022, Pfizer announced a strategic partnership with Bristol-Myers Squibb to expand their portfolio of cardiovascular drugs, which also targets arrhythmias. Europe follows closely, with companies like Sanofi and Novartis actively engaging in research collaborations to improve drug efficacy and patient outcomes. Recently, Novartis launched a new drug in the European market aimed at reducing the recurrence of atrial fibrillation, addressing a significant unmet need. Asia-Pacific is rapidly emerging as a key region, with growing investments in R&D by regional players like Takeda Pharmaceuticals. In 2023, Takeda announced a merger with a local biotech firm to expand its portfolio of cardiovascular drugs, signaling increased competition and innovation in the region's antiarrhythmic drugs market.

Recent Developments:

In May 2024, Milestone Pharmaceuticals Inc. partnered with Arrhythmia Alliance to promote awareness of supraventricular tachycardia (SVT). This collaboration aims to improve education and understanding of the condition, highlighting Milestone's commitment to innovative cardiovascular treatments.

In December 2023, Acesion Pharma, a biotech firm focused on innovative therapies for atrial fibrillation, announced the publication of its Phase 2 proof-of-concept trial results for AP30663, a groundbreaking SK ion channel inhibitor, in Nature Medicine.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTIARRHYTHMIC DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Abbott Laboratories
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Harlan Laboratories, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Others

GLOBAL ANTIARRHYTHMIC DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Sodium Channel Blockers
  • Beta-Blockers
  • Potassium Channel Blockers
  • Calcium Channel Blockers

GLOBAL ANTIARRHYTHMIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable
  • Transdermal

GLOBAL ANTIARRHYTHMIC DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Atrial Fibrillation
  • Ventricular Tachycardia
  • Supraventricular Tachycardia
  • Other

GLOBAL ANTIARRHYTHMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL ANTIARRHYTHMIC DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Antiarrhythmic Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Antiarrhythmic Drugs Market Snippet by Drug Class
    • 2.1.2. Antiarrhythmic Drugs Market Snippet by Route of Administration
    • 2.1.3. Antiarrhythmic Drugs Market Snippet by Indication
    • 2.1.4. Antiarrhythmic Drugs Market Snippet by Distribution Channel
    • 2.1.5. Antiarrhythmic Drugs Market Snippet by Country
    • 2.1.6. Antiarrhythmic Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Antiarrhythmic Drugs Key Market Trends

  • 3.1. Antiarrhythmic Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Antiarrhythmic Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Antiarrhythmic Drugs Market Opportunities
  • 3.4. Antiarrhythmic Drugs Market Future Trends

4. Antiarrhythmic Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Antiarrhythmic Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Antiarrhythmic Drugs Market Landscape

  • 6.1. Antiarrhythmic Drugs Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Antiarrhythmic Drugs Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. Sodium Channel Blockers
    • 7.1.3. Beta-Blockers
    • 7.1.4. Potassium Channel Blockers
    • 7.1.5. Calcium Channel Blockers

8. Antiarrhythmic Drugs Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Injectable
    • 8.1.4. Transdermal

9. Antiarrhythmic Drugs Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 9.1.2. Atrial Fibrillation
    • 9.1.3. Ventricular Tachycardia
    • 9.1.4. Supraventricular Tachycardia
    • 9.1.5. Other

10. Antiarrhythmic Drugs Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Antiarrhythmic Drugs Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Antiarrhythmic Drugs Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Antiarrhythmic Drugs Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Antiarrhythmic Drugs Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Antiarrhythmic Drugs Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Antiarrhythmic Drugs Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Antiarrhythmic Drugs Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Abbott Laboratories
    • 12.2.2. Amgen Inc.
    • 12.2.3. Astellas Pharma Inc.
    • 12.2.4. AstraZeneca PLC
    • 12.2.5. Bayer AG
    • 12.2.6. Boehringer Ingelheim GmbH
    • 12.2.7. Bristol-Myers Squibb Company
    • 12.2.8. Gilead Sciences, Inc.
    • 12.2.9. GlaxoSmithKline plc
    • 12.2.10. Harlan Laboratories, Inc.
    • 12.2.11. Johnson & Johnson
    • 12.2.12. Merck & Co., Inc.
    • 12.2.13. Novartis AG
    • 12.2.14. Pfizer Inc.
    • 12.2.15. Sanofi S.A.
    • 12.2.16. Teva Pharmaceutical Industries Ltd.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us